Hypoxic inducible factor (HIF). HIF itself functions as a hypoxic condition. Hypoxia triggers production of several mediators such as hypoxic inducible factor (HIF)-1α, vascular endothelial growth factor (VEGF), and transforming growth factor (TGF)-β1. The mediators act in liver fibrosis and cirrhosis, and hepatocellular carcinoma.

**AIM:** The objective of the study was to determine the difference in serum HIF-1α, VEGF, and TGF-β1 levels based on liver fibrosis severity in patients with chronic hepatitis B.

**MATERIALS AND METHODS:** This cross-sectional study was performed in Haji Adam Malik Hospital Medan, Indonesia, from January to July 2020. Subjects were chronic hepatitis B patients aged 18 years or older. Exclusion criteria were other chronic diseases, malignancies, or pregnancy. Liver fibrosis was determined using shear wave elastography and categorized as follows: F1, F2, F3, and F4. Serum HIF-1α, VEGF, and TGF-β1 levels were measured using enzyme-linked immunosorbent assay. Specimens were obtained from venous blood.

**RESULTS:** A total of 63 patients were enrolled in this study with mean age of 40.3 (SD 11.69) years. Subjects were dominated by males (58.7%). There were no differences in serum HIF-1α, VEGF, and TGF-β1 levels based on liver fibrosis grading and also based on hepatitis B envelope antigen (HBeAg) status and gender. Associations were dominated by males (58.7%). There were no differences in serum HIF-1α, VEGF, and TGF-β1 levels were measured using enzyme-linked immunosorbent assay. Specimens were obtained from venous blood.

**CONCLUSION:** Serum HIF-1α, VEGF, and TGF-β1 levels were not different among chronic hepatitis B patients based on liver fibrosis severity.

**Introduction**

Hepatitis B infection is a serious global health problem. Approximately 240 million of world’s population is infected with hepatitis B virus (HBV). Hepatitis B infection increases the risk of liver cirrhosis, liver decompensation, and hepatocellular carcinoma [1], [2]. The prevalence of hepatitis B infection is the highest in Asia-Pacific region [3]. In Indonesia, the prevalence of hepatitis B patients ranges from 4.0% to 20.3% [4]. HBV is transmitted vertically and horizontally. Around 90% of vertically transmitted infection in perinatal period will become chronic while only 5% of adult cases grow chronic [5].

Liver fibrosis results from chronic infection, including HBV infection, which causes hepatocyte death and its replacement with fibrous tissue. This process triggers hypoxia condition that activates hypoxic inducible factor (HIF). HIF itself functions as regulator of vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-β1 [6], [7], [8], [9].
fibrosis severity from liver elastography examination. We hoped that serum HIF-1α, VEGF, and TGF-β1 may play important role in predicting liver fibrosis severity in resource-limited health centers.

Materials and Methods

This cross-sectional study was performed in outpatient clinic of Haji Adam Malik Hospital Medan, Indonesia. The study period ranged between January and July 2020. Subjects were chronic hepatitis B patients aged 18 years or older. Subjects with other chronic diseases, malignancies, or who were pregnant were excluded from this study. Written informed consent was obtained from each subject. Baseline characteristics were gathered from direct interview. Liver fibrosis was determined using shear wave elastography. Numerical results were expressed in kPa while categorical grades were determined as follows: F1 (<7.1 kPa), F2 (7.1–9.3 kPa), F3 (9.3–14.5 kPa), and F4 (>14.5 kPa). Serum HIF-1α, VEGF, and TGF-β1 levels were measured using enzyme-linked immunosorbent assay. Specimens were obtained from venous blood. Serum HIF-1α level was expressed in ng/mL while serum VEGF and TGF-β1 levels in ng/mL. Data analysis was done with statistical software and the results will be presented in tables. This study was approved by the Health Research Ethical Committee, Medical School, Universitas Sumatera Utara.

Results

A total of 63 patients were enrolled in this study. Mean age of subjects was 40.3 (standard deviation [SD] 11.69) years. Male subjects were dominant in this study (58.7%). Subject's distribution based on fibrosis grading was roughly equal. Of all subjects, 20 were naïve patients and 27 were hepatitis B envelope antigen (HBeAg) reactive. Mean fibrosis severity of subjects in this study was 7.9 kPa. Median serum HIF-1α level, VEGF, and TGF-β1 level were 0.09 ng/mL, 561.9 ng/L, and 37.0 ng/L, respectively (Table 1).

Based on statistical analysis, we did not observe any difference in serum HIF-1α, VEGF, and TGF-β1 levels based on liver fibrosis grading. In this study, the highest serum HIF-1α level was observed in F1 group. In contrast, serum VEGF and TGF-β1 levels were highest in F3 group (Table 2).

We further evaluate the associations between liver fibrosis staging and HBeAg status and gender. There was no statistically significant association between liver fibrosis staging and HBeAg status (p = 0.335). Similar result was observed in the association between liver fibrosis staging and gender (p = 0.459) (Table 3).

The severity of liver fibrosis was also measured in numerical scale. Based on HBeAg status and gender, there was no statistically significant difference in severity of liver fibrosis with p values of 0.335 and 0.327, respectively (Table 4).

We also analyzed the correlation between liver fibrosis severity and age of subjects. We found a positive significant correlation between both variables (r = 0.311, p = 0.013). The higher the age of subjects, the more severe the liver fibrosis becomes (Table 5).
Discussion

Chronic hepatitis B is initiated by unresolved acute hepatitis B infection, marked by the presence of HBsAg and HBV DNA. HBeAg, in the other hand, is a marker of high viral load and could be remained positive in months to years after the onset of infection [16]. As time goes by, liver damage will occur. At first, hepatocytes experience damage and apoptosis. This will impair hepatic blood circulation and induce hypoxic condition. Those situations induce secretion of fibrogenic mediators which activate hepatic stellate cells (HSCs) to produce fibrous connective tissues [17], [18].

HIF is one of mediators secreted in hypoxic condition. It consists of HIF-1α and HIF-1β heterodimers [19], [20], [21]. HIF plays important role in maintaining tissue oxygenation by promoting cell metabolism, proliferation, and migration [21], [22]. Most organs follow the same rule, including liver. HIF, in the other hand, is also related to VEGF and TGF-β1 which promotes fibrogenesis through HSC activation [23], [24].

In acute liver injury, HIF-1α has protective effect but not in chronic liver disease [18], [25], [26]. HIF-1α increases the activities of fibrogenesis and angiogenesis in chronic liver disease [21]. Chronic liver damage results in extracellular matrix accumulation, including fibrocytes, replacing damaged liver tissues [18]. In an animal study, administration of HIF-1α inhibitor resulted in alleviation of liver damage and ablation of liver failure. This was suspected from decreased reactive oxygen species amount, inhibited necrosis process, and decreased hepatocyte mitochondria permeability due to inactivation of HIF-1α [26]. Liver fibrosis was also less progressive in HIF-1α knockout mice even after receiving similar treatment with normal mice. This finding supported the theory that HIF-1α plays important role in fibrogenesis in liver damage [27]. Another study in mice showed positive association between HIF-1α expression and liver fibrosis severity. In addition, HIF-1α expression was also correlated with angiogenesis and VEGF expression. In this study, HIF-1α expression was measured histopathologically [28]. Those studies were not in line with our result. We did not observe a difference in serum HIF-1α level based on liver fibrosis grading. Furthermore, median serum HIF-1α level was higher in subjects with mild grade liver fibrosis.

Even though the highest serum VEGF level in this study was observed in F3 grade, the difference was no statistically significant compared to F1 and F2 grades. There are still controversies regarding this finding. The expression of VEGF was increased in hypoxia condition and related to angiogenesis. Its expressions were different among liver diseases and the highest was in acute hepatitis. In chronic hepatitis, the expression of VEGF was not increased compared to healthy subjects as control. Serum VEGF level was also not in line with inflammation score in chronic hepatitis and liver cirrhosis [29]. Our result is in contrast with a study by El-Assal et al. [30]. They reported that tissue VEGF expression was higher in liver cirrhosis patients compared to subjects without liver cirrhosis. However, they also did not find any association between tissue VEGF expression and histopathology findings in patients with hepatocellular carcinoma. This might be caused by decreased VEGF role after the tumor reached a significant size [31]. In the other hand, serum VEGF level per thrombocyte count was associated with the severity of liver cirrhosis based on a study from Korea. The higher the serum VEGF level per thrombocyte count, the lower the therapeutic response of patients and this was obviously related to poor disease outcome [7]. Another study from Indonesia reported that serum VEGF level was associated with disease progressivity of liver cirrhosis. Serum VEGF level is in concordance with liver cirrhosis severity based on Child Pugh scoring system [8].

TGF-β is involved in the pathogenesis of disease from liver fibrosis to hepatocellular carcinoma [18], [31]. A study by Yang et al. showed that TGF-β expression was increased in the hepatic tissue of mice suffering from liver fibrosis and hepatocellular carcinoma. The elevation of TGF-β expression was suspected to increase fibrogenesis, anti-apoptotic, pro-oncogenic, and angiogenic activities in hepatocytes [31]. An in vitro study proved that the addition of TGF-β significantly increased collagen I and fibronectin levels which led to liver fibrosis. Administration of TGF-β inhibitor (ferulic acid) resulted in fibrogenesis inhibition [32]. The expression of TGF-β1 in hepatic tissues of mice suffering from fibrosis was increased according to a study by Fan et al. The increment was followed by increased activity of HSC, one of important cells that promote fibrogenesis activity. They also found that extracellular matrix protein 1 secreted by hepatocytes might inhibit TGF-β1 activity [33]. Our result was different with several literatures above. Serum TGF-β1 level was not significantly different based on fibrosis grading but we found that subjects with severe grade fibrosis had the highest serum TGF-β1 level.

In this study, male subjects were dominant. Males were also dominant in each grade of fibrosis group. The severity of liver fibrosis was higher in males compared to females even though the difference was not statistically significant. Male predilection in liver fibrosis could be caused by the difference in the lifestyle. Males were prone to high risk lifestyles compared to females such as alcohol consumption, smoking, and unhealthy diet [18], [31], [34]. According to Yang et al. males had higher risk for liver fibrosis due to the absence of estrogen. This was supported by the fact that gender predisposition began to disappear by age [35].

Gao et al. found that hepatitis B infection markers which associated with liver fibrosis severity were not HBeAg, but HBsAg and HBV DNA. Uniquely, HBsAg and HBV DNA levels in patients with moderate
and severe grades fibrosis were lower compared to those with mild grade [36]. Analysis result by Chen et al. showed that qualitative HBeAg level was positively associated with liver fibrosis severity [37]. In this study, HBeAg was measured qualitatively and most subjects were not reactive. Those might affect the result of our study, where there was no relationship between HBeAg status and fibrosis grading in this study. The severity of liver fibrosis was also milder in subjects with reactive HBeAg but the difference was not statistically significant.

Petta et al. conducted a study in 2017. They reported that age was a factor influencing the severity of liver fibrosis. The relationship was mediated by lipid profile. The older the subject, the more severe liver fibrosis became [38]. Similar result was reported by Klisic et al. They stated that advanced age was an independent risk factor for the severity of liver fibrosis. In their study, the severity of liver fibrosis was assessed using BARD score [39]. Another study confirming those findings were reported by van Santen et al. Advanced age was associated with more severe fibrosis. In their study, liver fibrosis severity was measured using similar method with our study [40]. Our result was consistent with previous studies results. We found a positive correlation between age and liver fibrosis severity.

There were some differences in our result with previous studies. This might be caused by our study’s limitations. We examined the level of mediators from serum sample while most previous studies used histopathological method from tissue specimen. Besides, there was a difference in fibrosis grading evaluation. Regardless of that, according to authors’ knowledge this was the first study determining the difference in serum HIF-1α, VEGF, and TGF-β1 levels based on liver fibrosis severity in general population, not study animal, in Indonesia.

As the conclusion, there was no difference in serum HIF-1α, VEGF, and TGF-β1 levels based on severity of liver fibrosis in this study. Similar result was reported based on HBeAg status and gender. There was no association between liver fibrosis grading and HBeAg status and gender. Positive correlation was observed between severity of liver fibrosis and age.

References

Husen et al. HIF-1α, VEGF, TGF-β1 in Liver Fibrosis


PMid:9508533


PMid:9620326


PMid:23391818


PMid:30584275


PMid:31362006


PMid:30106760


PMid:24123276


PMid:26133815


PMid:30405859


PMid:28235154


PMid:30784251


PMid:30028776